Clinical trial · Observational
Cousin vs. Sibling Donors in Haplo-HSCT
Comparison of Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation From Cousin Donors Versus Sibling Donors in Patients With Hematological Malignancies: A Target Trial Emulation Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This observational study aims to emulate a hypothetical pragmatic, multicenter, non-blinded clinical trial enrolling adult patients undergoing haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with grafts derived from either cousin or sibiling donors. The main research question is whether cousin donor-derived haplo-HSCT is associated with inferior clinical outcomes relative to sibling donor-derived haplo-HSCT. Study participants consist of adult patients diagnosed with hematological malignancies who underwent cousin or sibiling haplo-HSCT between 2017 and 2024, and all eligible recipients will receive regular follow-up assessments.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Donor | — | UNRESOLVED | — |
| Haploidentical Hematopoietic Stem Cell Transplantation | — | UNRESOLVED | — |
| Hematopoietic Malignancies | Hematopoietic and Lymphoid Cell Neoplasm | PROBABILISTIC | 0.70 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Cousin haplo-HSCT
- description
- Patients who underwent haploidentical hematopoietic stem cell transplantation with cousin donors. Grouping was based on donor age recorded in retrospective clinical data.
- label
- Sibling haplo-HSCT
- description
- Patients who underwent haploidentical hematopoietic stem cell transplantation with sibling donors. Grouping was based on donor age recorded in retrospective clinical data.
Primary outcomes (4)
- measure
- Overall survival
- timeFrame
- 2 years after transplantation
- description
- estimated overall survival at 2 year
- measure
- Graft-versus-host disease-free and relapse-free survival
- timeFrame
- 2 years after transplantation
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients diagnosed with hematological malignancies, including acute leukemia (AL), chronic myeloid leukemia (CML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), and non-Hodgkin lymphoma (NHL) * Receipt of first haploidentical hematopoietic stem cell transplantation between 2017 and 2024 * Documented exact date of transplantation available in medical charts * Verifiable donor kinship classified as either cousin or sibiling * Complete longitudinal follow-up data accessible for outcome assessment Exclusion Criteria: * Prior receipt of any form of hematopoietic stem cell transplantation * An age difference of more than 18 years between the donor and recipient * Failure of successful infusion of donor-derived hematopoietic stem cells following conditioning regimen
References
Publications (0)
Data not yet available